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Sulphur mustard (SM) is an alkylating agent with cytotoxic, mutagenic and vesicating 
properties. The underlying mechanisms of SM pathology are not fully understood. 
Inhalation of SM can lead to persistent and clinically significant lung disease, 
including bronchial mucosal injury, many years after exposure. There is no known 
medical countermeasure for SM-induced respiratory injuries.   
We hypothesized that inflammatory mechanisms play an essential role in SM 
pathogenesis and interrupting the inflammatory cascade may ameliorate SM-induced 
injuries, especially in the lungs. Previous studies have shown des-aspartate-
angiotensin I (DAA-1) treatment over 14 days was able to increase survival numbers 
of mice intoxicated intranasally with 2-chlorethyl-ethyl sulfide (CEES), a less toxic 
analog of SM. DAA-1, a bioactive angiotensin peptide, was known to have an effect 
on the angiotensin II proinflammatory pathway.  
This project aimed to complement this previous work. The main of the project is to 
determine if interrupting the angiotensin II inflammatory pathway with angiotensin 
IV (ANG-IV) treatment could improve survival rate of SM-intoxicated mice and 
protect against SM-induced pulmonary biochemical and histopathological changes. 
ANG-IV have been shown to effectively modify angiotensin II pathways. DAA-1 and 
losartan were also investigated alongside ANG-IV treatment.   
_____________________________________________________________________    
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We developed an intranasal SM mice model to study survival rate and pulmonary 
damages in intoxicated animals. A single LD80 SM was administered 
(0.006mg/mouse) and treatments were given 60 minutes before SM administration, 
followed by a daily dose for 14 days post-SM. The effectiveness of different drugs in 
improving survival rate, mediating weight loss and reducing pulmonary inflammation 
of the intoxicated animals were evaluated over 21 days.   
It was observed that treatment with 150 nm/kg/day ANG-IV and 150 nm/kg/day 
DAA-1 improved survival rate and reduced body weight loss of SM intoxicated mice 
and were effective in lowering pulmonary inflammatory markers (MPO and 
histopathology) caused by SM intoxication. SM-intoxicated mice treated with either 
ANG-IV or DAA-1 showed considerable suppression of pulmonary edema, 
parenchymal damage and concurrent reduction in MPO (neutrophil infiltration 
indicator). We also demonstrated that ANG-IV exerted its protective action via both 
AT4 and AT1 receptors as divalinal ANG-IV (AT4 antagonist) and losartan (AT1 
antagonist) were able to antagonize its protective effects in SM intoxicated mice.  
Hence, the results of this study supported our hypothesis that SM-induced pulmonary 
damages can be mediated by attenuating inflammation via the angiotensin II pathway 
at the injury site. These anti-inflammatory compounds may represent a novel and 
specific therapeutic strategy for treatment of SM-induced pulmonary lesions and 
understanding its pathogenesis. 
_____________________________________________________________________ 
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Chapter 1 Introduction 
 
Sulphur mustard (SM; 2, 2 -dichlorethyl sulfide) is an alkylating chemical warfare 
agent with cytotoxic, mutagenic and vesicating properties. It affects mainly the eyes, 
skin and respiratory system, causing debilitating injuries that require extensive and 
prolonged medical attention. Symptoms include formation of blisters on the skin, loss 
of sight, vomiting and severe respiration difficulties.   
SM was used extensively during World War I and more recently in the Iran-Iraq War 
(1984-1988) (Borak, et al., 1992). As SM is easily and cheaply manufactured, it is 
considered a potential agent of terrorism. No effective therapy is available but SM-
induced damages to skin can be treated with skin transplants. Although most fatalities 
are often due to pulmonary damages and related secondary infections from SM 
inhalation (Papirmeister, et al., 1991), no specific treatment is currently available for 
SM-induced respiratory lesions.   
Inhalation of SM can lead to persistent and clinically significant lung diseases, even 
many years after exposure. Forty-five thousand Iranians victims of the Iran-Iraq war 
are now still suffering from severe chronic respiratory disorders due to mustard gas 
exposure almost 20 years ago (Ghanei, et al., 2007 and Balali-Mood, et al., 2006). 





Although much research has been conducted in this area, the underlying mechanisms 
of SM pathology are not fully understood. Understanding the pathophysiological 
processes of SM inhalation injury will enable the development of effective treatment 
regimes to prevent or reduce the development of SM-induced lesions as well as to 
shorten the period of healing.   
Previous research has been focused on the prevention of cell death with drugs that 
prevented the alkylation of DNA, cytotoxic mechanisms and mutagenesis (Smith, 
2008). However, there has been increasing interest in the role of inflammation in the 
development and sustainment of SM-induced injuries. Initial studies have shown that 
symptoms of inflammatory process actually preceded typical SM histopathological 
damage in the basal layer (Ricketts, et al., 2000). Hence, it was hypothesized that 
inflammatory mechanisms play an essential role in the initiation and progress of SM 
pathogenesis and interrupting the inflammatory cascade may ameliorate SM-induced 
injuries, especially that in the lungs.   
Angiotensin II is the major effector molecule produced from the renin-angiotensin-
aldosterone system and has been shown to downregulate peroxisome proliferators-
activated receptors, which have anti-inflammatory effects (Tham, et al., 2002). In 
bleomycin induced lung injury in vivo, increased angiotensin II activation was 
observed in endothelial cells, mesothelial cells and macrophages within the fibrotic 
lesions (Marshall, 2003). Angiotensin II has been identified as a pro-apoptotic factor 





was found to occur early in lung injury and these were some of the symptoms 
(fibrotic lesions and alveolar destruction) commonly observed in SM-induced 
pulmonary damage (Vijayaraghavan, et al., 2005).   
Previous studies (Ng, 2007) have shown that daily des-aspartate-angiotensin I (DAA-
1) treatment over 14 days  was able to increase survival numbers of mice intoxicated 
with 2-chlorethyl-ethyl sulfide (CEES), a less toxic analog of SM. DAA-1, a 
bioactive angiotensin peptide, was known to have an effect on the angiotensin II 
proinflammatory pathway. DAA-1 treatment was also found to be able to attenuate 
weight loss, neutrophil infiltration and alveolar cell damage in CEES-exposed 
animals.    
This project aimed to complement the previous work (Ng, 2007) in investigating the 
anti-inflammatory effects of angiotensin II interruption as means of mitigating SM 
induced lung injury and mortality. The hypothesis of the project was that 
inflammatory processes play a key role in the development and sustainment of SM-
induced injuries.   
We were interested to determine if interrupting the angiotensin II inflammatory 
pathway with angiotensin IV (ANG-IV) treatment could improve the survival rate of 
SM-intoxicated mice and protect against SM-induced pulmonary biochemical and 
histopathological changes. However, since earlier studies (Ng, 2007) have shown that 





with 2-chlorethyl-ethyl sulfide (CEES), a less toxic analog of SM, also know as half 
sulphur mustard, DAA-1 was also investigated alongside ANG-IV treatment for this 
study as means of comparison.   
ANG-IV, a short angiotensin peptide and a metabolite of angiotensin II and DAA-1, 
has been shown to effectively modify angiotensin II pathways (Loufrani, et al., 1999). 
DAA-1 and losartan were also investigated alongside ANG-IV treatment, to 
determine their protective efficacies against lethal SM intranasal challenge. We were 
also interested to compare the protective anti-inflammatory effects of DAA-1 against 
a more aggressive and toxic chemical like SM as it was shown to be effective in 
attenuating damage by a less toxic analogue, CEES, in earlier studies (Ng, 2007). 
These anti-inflammatory compounds may represent a novel and specific therapeutic 
strategy for the treatment of SM-induced respiratory lesions and shed light on 
underlying mechanisms of SM-induced pathology. 
 _____________________________________________________________________ 
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Chapter 2  Literature Review 
2.1 Sulphur Mustard overview  
Sulphur mustard (SM; 2, 2 -dichlorethyl sulfide) is a potent blistering and alkylating 
agent (Somani, et al., 1989). It has little commercial value other than its role in 
chemical warfare. SM was used extensively during World War I and more recently in 
the Iran-Iraq War (1984-1988) (Borak, et al., 1992). It is easily and cheaply 
manufactured, hence, it is considered a potential agent of terrorism.   
SM, a pale yellow oily liquid, has been shown to aerosolize when dispersed by 
spraying or by explosive blast (Borak, et al., 1992).  It has low volatility and has been 
found to be very persistent in the environment, increasing the risk of further exposure 
to people. The chemical formula and physical properties of sulphur mustard is 
presented in Table 1.  
SM has cytotoxic, mutagenic and vesicating properties (Papirmeister, et al., 1985) 
and has been demonstrated to be capable of initiating free radical-mediated oxidative 
stress (Omaye, et al., 1991). Debilitating SM-induced injuries required extensive and 
prolonged medical attention. Symptoms included formation of blisters on the skin, 





Table 1: Chemical formula and physical properties of sulfur mustard  
(Adapted from Figure 1; Borak, et al., 1992)  
2,2'-dichlorethyl sulfide  
 
Colourless or pale yellow oily liquid 
Boiling point, 215-217.2 ºC 
Vapour pressure, 0.9 mm Hg at 30 ºC 
Vapour density, 5.4 
Sparingly water soluble (0.68 gm/L at 25 ºC) 
Odour of mustard or garlic 
Clinical symptoms of SM exposure occurred with direct contact with skin and eye or 
via inhalation. The onset of symptoms usually occurred after a latent period of 4 to 12 
hours post-SM exposure (Borak, et al., 1992). Higher concentrations and longer 
duration exposures have cause symptoms to develop more rapidly. Although fatality 
rates due to SM exposure were low, SM victims suffered from multiple sites of severe 
incapacitating injuries with delayed healing (Dunn, 1986). Skin burns were painful, 
easily infected and notoriously slow to heal. In addition, inhalation of SM can lead to 
persistent and clinically significant chronic lung diseases, even many years after 
exposure. Forty-five thousand Iranians victims of the Iran-Iraq war are now still 
suffering from severe chronic respiratory disorders due to mustard gas exposure 
almost 20 years ago (Ghanei, et al., 2007 and Balali-Mood, et al., 2006). Their 
clinical symptoms include bronchiolitis, asthma, emphysema and brochiectasis. Death 








However, although many of the toxic manifestations of SM exposure to cells and 
tissues have been defined, the underlying mechanisms of SM pathology have yet to 
be elucidated. In addition, the chronological events in cell and tissue injury following 
SM exposure, such as the relationship between cytotoxic mechanisms induced by SM 
and the subsequent development of tissue damage, have not been clearly 
characterized.  
No effective therapy or antidote is currently available but SM-induced damages to 
skin have been successfully treated with skin transplants. However as most fatalities 
were often caused by pulmonary damages and related secondary infections from SM 
inhalation (Papirmeister , et al., 1991), it is of much concern that no specific treatment 
is currently available for SM-induced respiratory lesions.   
2.2 Inflammation in SM-induced pathology  
There has been increasing interest in the role of inflammation in the progress of SM-
induced injuries. Initial studies have showed that symptoms of inflammatory process 
have in fact preceded typical SM histopathological damage in the basal layer 
(Ricketts, et al., 2000). Thus, it was hypothesized that inflammatory mechanisms play 
an essential role in the pathogenesis of SM and interrupting the inflammatory cascade 
may ameliorate SM induced injuries, especially that in the lungs.   
Understanding the pathophysiological processes of SM inhalation injury would 





development of SM-induced lesions as well as to shorten the period of healing. 
Although respiratory tract damages due to inhalation of SM were the main source of 
morbidity and mortality, the pathophysiology and inflammatory processes involved 
have not been determined. Inflammation in SM pathogenesis may involve a cascade 
of proinflammatory mediators and complex interactions between different 
proinflammatory cells. The recent studies investigating the role of inflammation in 
SM toxicity have been consolidated in Table 2.  
Table 2: Representative studies investigating the role of inflammation in SM 
pathogenesis 
Authors Year Route of 
SM 
exposure 
















Calvet, et al. 1999 Intra- 
tracheal 
study 
Guinea pigs Neutrophils, 
Macrophages
, Gelatinases 





Rats Neutrophils  24hrs  N- 
acetylcysteine  
Arroyo, et al. 
 
2003 In vitro Human skin 
fibroblast  











24hrs  Doxycycline 
Emmler, et 
al.  
2007 In vitro Human alveolo- 
capillary co-
cultures 
IL-6, IL-8 24hrs  N.A. 
Gao, et al. 2007 In vitro Human respiratory 
epithelial cells 
IL-6, IL-8  IL6: 3hrs  
IL8: 5hrs  
Roxithromycin  
These studies (Table 2) have shown that inflammation play a primary role in 
initiating pathogenesis of SM-induced lesion by triggering a cascade of 





melphalan, an alkylating agent like SM, have also demonstrated the activation of a 
proinflammatory response very early after melphalan exposure (Osterlund, et al., 
2005). In fact, the upregulation of stress-induced mitogen activated phosphorylated 
kinases (MAPK) was observed as early as 5 minutes post- melphalan exposure with 
the translocation of nuclear factor (NF)-kB into the cell nuclei within 45 minutes. 
Elevated levels of TNF- and intercellular adhesion molecule-1 (ICAM-1) were also 
observed. ICAM-1, a proinflammatory mediator, have been known to propagate the 
tissue inflammation process by the promotion of inflammatory cells transmigration 
across the epithelium airway (Lin, et al., 2005).  
Mast cell degranulation and the presence of inflammatory mediators such as 
histamine have been observed in SM-exposed human skin explants (Rikimaru, et al., 
1991). Mast cell degranulation, an early event in the inflammatory pathway, released 
a number of proinflammatory mediators, including chemotactic cytokines that 
attracted specific cells like neutrophils (Klein, et al., 1989).   
In a rat model experiment using 2-chlorethyl-ethyl sulfide (CEES), a less toxic analog 
of SM, significant attenuation of pulmonary injury have been observed with depletion 
of neutrophils or complement prior to intratracheal administration of CEES 
(McClintock, et al., 2002). Previous work in the lab has also demonstrated the 
upregulation of inflammatory mediators, such as neutrophils infiltration and ICAM-1 
levels, in the lungs of mice exposed to CEES (Ng, 2007). Thus, these findings support 





early stage development of SM-induced acute lung injuries.   
Inflammation is a complex and dynamic process that involves different cell 
populations and chemical mediators responding to different stimuli. Differences in 
physical or chemical insults affect the type, kinetics and location of inflammatory 
infiltrates activated in response to the specific inflammatory agent encountered 
(Cowan, et al., 1993). Thus, it may be possible for SM to activate a specific and 
unique set of inflammatory responses. The characterization of the inflammatory role 
in SM-induced pathogenesis and the development of anti-inflammatory compounds 
could be an essential therapeutic intervention that may interrupt the damage caused 
by SM.    
2.3   Current Treatment Strategies  
The first priority in handling potential SM intoxication would be to remove victims 
from the contaminated areas and immediately commence decontamination procedures 
to flush off any residual SM present on the victim (Borak, et al., 1992). This is 
because SM would become fixed in the tissues within minutes of exposure and the 
resultant injury progression would be irreversible. After the decontamination process, 
only general supportive care is available for the patients as no effective treatment is 





Presently, studies in the different toxic events induced by SM, such as formation of 
DNA strand breaks, disruption of calcium regulation, and tissue inflammation have 
led to the formation of six potential strategies for medical countermeasures (Table 3). 
However, these compounds were mainly evaluated as therapeutic interventions 
against SM skin-induced toxicity (Smith, 2008).  
Table 3: Treatment strategies for SM-induced pathogenesis  
(Adapted from Table 1; Smith, 2008)  
Biochemical event Pharmacologic strategy 
DNA alkylation Intercellular scavengers 
DNA strand breaks Cell cycle inhibitors 
PARP activation PARP inhibitors 
Disruption of calcium Calcium modulators 
Proteolytic activation Protease inhibitors 
Inflammation Anti-inflammatories 
 
Current research direction has also been moving towards the early administration of 
drugs with anti-inflammatory (Dachir, et al., 2004 and Dillman, et al., 2006) and free 
radical scavenging properties (Anderson, et al., 2000 and Arroyo, et al., 2003) to 
mediate against SM-induced damages on epithelial tissues. Antibiotics, like 
doxycycline (Guignabert, et al., 2005) and roxithromycin (Gao, et al., 2007), have 
exhibited beneficial anti-inflammatory effects on cells lines exposed to SM and it was 
proposed that these antibiotics reduced inflammation via mechanisms independent of 





However, such treatment modalities have displayed a limited therapeutic window 
post-SM exposure. It was demonstrated that current steroids/NSAID generic anti-
inflammation treatment was not able to completely prevent the resultant cytotoxic 
processes in the epithelial layer (Arroyo, et al., 2003). Thus, although the release of 
inflammatory mediators such as Prostaglandin E was reduced, extensive damage to 
the epithelial layer was not prevented. In addition, the mechanisms at which 
antibiotics suppress inflammatory mediators were unknown and it was also observed 
that antibiotics, like roxithromycin, altered the morphology of cell lines after 
treatment (Gao, et al. 2007). Thus, there were still many limitations and uncertainties 
in using drugs like steroids/NSAID or antibiotics for the treatment of SM-induced 
lesions.   
Inflammation in the pathogenesis of SM-induced lesions would involve a cascade of 
proinflammatory mediators and a complex network of discrete cell populations 
dynamically interacting with each other. Thus, in order to effectively mediate the 
massive onslaught of inflammatory processes triggered by SM exposure, we 
hypothesized that it would be worthwhile to target and inhibit specific mediators 
present upstream in the inflammatory cascade. Hence, a prominent potent 
proinflammatory mediator upstream in the inflammatory cascade would be 





2.4 Pulmonary Renin-Angiotensin system (RAS)  
Angiotensin II is the major effector molecule produced from the renin-angiotensin-
aldosterone system (Marshall, 2003). In the RAS, angiotensinogen is cleaved by renin 
to form angiotensin I, which is converted to angiotensin II by angiotensin converting 
enzyme in the lungs. The activation of pulmonary RAS within the lung parenchyma 
and circulation have been found to influence the pathogenesis of lung damage via the 
upregulation of mechanisms involved in vascular permeability, fibroblast activity and 
alveolar epithelial cell death (Marshall, 2003).   
High concentrations of angiotensin II have been found in normal rat lungs and 
reported to have increased during radiation-induced pulmonary fibrosis (Song, et al., 
1998). The infusion of angiotensin II have been also shown to result in pulmonary 
edema and influence microvascular permeability in a rabbit model (Takatsugu, et al., 
2007), although the exact mechanisms remained unclear.  
Studies have shown that the activation of AT1 receptors by angiotensin II have 
resulted in proinflammatory (NF)-kB activation and AT1 receptors blockage (with 
angiotensin II receptor blockers - ARBs or angiotensin-converting enzyme inhibitors 
- ACEs) have contributed to anti-inflammatory outcomes (Dagenais, et al., 2005). 
Interestingly, NF-kB activation have resulted in the upregulation of various cytokines 
and adhesion molecules (Monaco, et al., 2004), including TNF- , IL-6 and IL-8, 
which were also found to be upregulated in tissues subjected to SM exposure 





angiotensin II have been demonstrated to downregulate peroxisome proliferators-
activated receptors, which have anti-inflammatory effects (Tham, et al., 2002).   
In bleomycin induced lung injury in vivo, an increased ACE expression was observed 
in endothelial cells, mesothelial cells and macrophages within the fibrotic lesions 
(Marshall, 2003). Administration of either losartan (AT1 receptor antagonist) or 
ramipril (ACE inhibitor) was able to suppress lung angiotensin II activation and 
collagen deposition. Research has also shown that human lung fibroblasts from 
patients with pulmonary fibrosis were found to generate angiotensin II (Wang, et al., 
1999).   
In a separate guinea pig asthma model study, treatment with specific ARBs was found 
to reduce bronchoconstriction reactions and immune cells accumulation (Myou, et al., 
2000). Alveolar epithelial cell death occurs early in lung injury and angiotensin II has 
been identified as a pro-apoptotic factor for alveolar epithelial cell in vitro (Wang, et 
al., 1999). These data support the hypothesis that endogenous angiotensin II was 
important in modulating airway hyper-responsiveness and enhancing the pulmonary 
inflammatory response observed during pulmonary injury. In fact, the different 
symptoms of lung pathology described in these experiments, were also observed in 
SM-induced lung injury.   
Angiotensin II have been found to activate the nicotinamide adenine dinucleotide-





(Rajagopalan, et al., 1996). Reactive oxygen species were shown to be upregulated in 
SM-induced lesion and free radical scavengers were able to reduce the upregulation 
of inflammatory mediators in SM models (Anderson, et al., 2000 and Arroyo, et al., 
2003).   
These factors suggest that angiotensin II may be one of the potential upstream 
proinflammatory mediators in the development of SM-induced inflammatory lesions. 
Thus, the interruption of angiotensin II activity may be essential in attenuating 
cellular damages and inflammation involved in the pathogenesis of SM injury.   
2.5 Bioactive angiotensin fragments  
Although angiotensin II has been considered the major effector molecule in the RAS, 
accumulating evidence (to be elaborated in the subsequent sections), have 
demonstrated that other peptides in the angiotensin pathway were also involved in a 
wide range of central and peripheral effects.   
Angiotensin II and its precursor angiotensin I are metabolized into bioactive 
angiotensin peptides by various enzymes (Figure A). Angiotensin I is degraded to 
angiotensin II via the action of angiotensin converting enzyme (ACE). The two 
angiotensin fragments utilized in this research are Angiotensin IV (ANG-IV) and des-
asp-angiotensin I (DAA-1). ANG-IV is obtained by the deletion of the N-terminal 





deletion of the N-terminal aspartic acid from angiotensin I by aminopeptidase X and 
aminopeptidase A.   
These angiotensin peptides regulate their cellular responses through binding to 
specific receptor subtypes. Angiotensin II and angiotensin III are full agonists at the 
type I angiotensin receptor (AT1) and also bind with high affinity at the type II 
angiotensin receptor (AT2) (Thomas, et al., 2003). ANG-IV display lower affinity for 
AT1 and AT2 receptors and have specific affinity at the type IV angiotensin receptor 
(AT4) (Loufrani, et al., 1999 and Ruiz-Ortega, et al., 2007). DAA-1 has been 
demonstrated to act through the AT1 receptor as the addition of losartan, an AT1 
antagonist, was able to negate DAA-1 anti-inflammatory effects observed in a 
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2.5.1 Angiotensin IV (ANG-IV)  
ANG-IV have been demonstrated to be involved in a wide range of central and 
peripheral effects, mediating important physiological functions such as blood flow 
regulation, learning and memory recall processes and anticonvulsant properties 
(Stragier, et al., 2008). ANG-IV binds with high affinity, selectively and reversibly to 
AT4 receptor binding site, identified as insulin-regulated aminopeptidase (IRAP) 
(Caron, et al., 2003 and Ruiz-Ortega, et al., 2007).   
IRAP is a type II integral membrane protein which colocalizes with the insulin-
responsive glucose transporter GLUT4 in the intracellular membrane vesicles (Keller, 
2004). The translocation of IRAP and GLUT4 to the plasma membrane occurs in the 
presence of insulin. Decreased expression of GLUT4 was found in IRAP knockout 
mice, thus supporting the hypothesis that the translocation of IRAP and GLUT4 may 
be impaired in type 2 diabetes patients (Keller, 2004).  
ANG-IV was found to be a competitive inhibitor of IRAP and studies in the brain 
have suggested that ANG-IV inhibition would extend the half life of certain bioactive 
peptides, thus regulating several responses, such as the enhancement of learning and 
memory (Chai, et al., 2004).  The presence of AT4 specific binding sites have also 
been found in various tissues, including kidneys, heart and blood vessels (Thomas, et 





ANG-IV has been reported to exhibit the properties of angiotensin II via activation of 
AT1 and AT2 receptors (Loufrani, et al., 1999). Studies have noted that ANG-IV 
induced reductions in renal artery blood flow could be blocked by Losartan, 
suggesting mediation by AT1 receptors (Gariner, et al., 1993 and Fitzgerald, et al., 
1999).  In an in vitro study using chick heart cells, ANG-IV was reported to block 
angiotensin II-induced RNA and protein synthesis (Baker, et al., 1990).   
In porcine pulmonary arterial endothelial cells, angiotensin II-induced NO release 
was demonstrated to be upregulated by ANG-IV (Hill-Kapturczak, et al., 1999). It 
was reported that the presence of divalinal-angiotensin IV (AT4 receptor blocker) 
blocked both the angiotensin II- and ANG-IV-induced NO release while AT1 and AT2 
blockage was unable to do so, indicating that the ANG-IV mediation was via AT4 
receptor.   
ANG-IV was also shown to play a important role in the regulation of translational 
signaling in lung endothelial cells, via increasing the phosphorylation of eukaryotic 
initiation factor 4E binding protein 1 (involved in RNA translation, cell growth and 
protein synthesis) (Lu, et al., 2005). In vitro studies have also shown that ANG-IV 
was able to induce lung endothelial cell proliferation by activating DNA synthesis 





2.5.2 DAA-1 (des-asp-angiotensin I)  
The formation of DAA-1 involves angiotensin I undergoing enzymatic NH2-terminal 
degradation to form DAA-1 and bypassing angiotensin converting enzyme (ACE) 
action that forms angiotensin II (Figure A). After which, DAA-1 would be further 
broken down by ACE to form angiotensin III (Blair-West, et al., 1971).   
It has been reported that endothelium and smooth muscle rat homogenates converted 
exogenous angiotensin I to DAA-1, as opposed to angiotensin II (Sim, 1993). In rat 
hypothalamic homogenate, this conversion was found to be facilitated by a novel 
specific aminopeptidase X (Sim, et al., 1994). It was observed that aminopeptidase X 
activity was elevated in hypertensive rat, indicating that the degradation of 
angiotensin I was shunted in favour of the DAA-1 pathway (Sim, et al., 1997). This 
suggested that DAA-1 could be associated with hypertension and blood pressure 
regulation.   
In isolated tissue studies, DAA-1 was able to induce relaxation in pre-contacted rabbit 
pulmonary trunk strips but further contract pre-contracted pulmonary artery strips 
(Sim, et al., 1996). However both these actions were inhibited by Losartan. DAA-1-
induced relaxation was inhibited by indomethacin, a compound known to inhibit the 





Daily DAA-1 treatment over 14 days was found to be able to attenuate weight loss, 
neutrophil infiltration, ICAM-1 levels and alveolar cell damage in mice intoxicated 
with 2-chlorethyl-ethyl sulfide (CEES), a less toxic analog of SM (Ng, 2007). The 
study also demonstrated that DAA-1 treatment, acting through the AT1 receptor, was 
also able to increase survival numbers of CEES-exposed animals.   
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Chapter 3  Materials and Methods 
3.1  Chemicals  
SM (>99% purity), was synthesized in DSO by the Organic Synthesis group and was 
diluted in 50% ethanol to the required concentration just before use. ANG-IV and 
DAA-1 were purchased from Sigma and Peptisytha (Belgium), respectively. Losartan 
was a generous gift from Merck.   
3.2  Animals  
Male Balb/C mice at 6-7 weeks of age, weighing between 20-25g were purchased 
from NUS Centre for animal resources (CARE) and housed in the Animal Holding 
Unit. The mice were quarantined for 1 week following arrival and their health status 
monitored daily. They were placed in plastic boxes with food and water freely given 
and exposed to 12 hour day/night cycle. All animal procedures were approved by 
DSO Institutional Animal Care and Use Committee (IACUC).  




3.3  Intranasal administration & the determination of SM lethal dose-
response plot in mice  
SM in 50% Ethanol was diluted to the required concentration. Mice were weight 
matched and studied in groups of 10. Mice were anesthetized by inhaled isofluorane 
(Nicholas Piramal, India) and 25µl of SM in 50% Ethanol was then delivered drop-
wise intranasally. 25 µl of 50% Ethanol was delivered intranasally to mice designated 
to be Vehicle control.   
To establish the toxicology lethal dose-response plot for SM, 9 different 
concentrations of SM in 50% Ethanol were used. The SM concentrations were in the 
range of 0.00125mg to 0.02mg (25µl per mouse). LD80 was found to be 0.006mg.   
After SM administration, the intoxicated mice were placed back into holding cages 
attached to a ventilated caging system (Thoren) to ensure that any off-gassing SM 
vapour from the nose of the animal was removed safely by a combination of carbon 
filters and ventilation systems connected to air scrubber systems fitted with 
detoxifying chemicals. After 24 hours, the mice were returned to their home cage 
where their weight and mortality were monitored for 21 days.   
All SM intranasal administration was performed in DSO, in a controlled area under a 
fume-hood with researcher using appropriate PPE, such as NBC mask, in accordance 
with the safety regulations of the centre.   




3.4  Establish therapeutic dose-response plot for the respective drugs (DAA-1, 
ANG-IV, and Losartan) for mice intranasal administration of SM  
To establish the therapeutic dose-response plot of the respective drugs, 5-6 difference 
doses of each drug were used. The drugs were diluted in filtered water. Mice were 
weight matched and studied in groups of 10 for each dose of each drug. The mice 
were given 0.1mL respective drugs 60min before SM administration (pretreatment). 
SM LD80 was administered intranasally to each mouse, as described in the paragraph 
3.3.   
0.1mL of respective drugs was given daily for 14 days, beginning with post-SM 
administration Day 1. The weight and mortality of the animals were monitored daily 
(until 21 days post-SM administration). DAA-1 and Angiotensin IV were given orally 
by gavage and Losartan was injected intraperitoneally.   
Based on the results obtained, 150 nmole/kg/day DAA-1 and 150 nmole/kg/day 
Angiotensin IV were selected for use in subsequent histological and biochemical 
studies.    
3.5  Histopathological evaluation  
At 6 different time-points (Post-SM administration Day 1, 4, 7, 10, 14, and 21), 3 
mice from each respective group (Vehicle, Control and Treatment) were anesthetized 




via intraperitoneal injection of 0.4-0.6 mg/g Avertin (Sigma) and sacrificed for 
histopathological evaluations. 3 clean mice (no treatment administered) were also 
sacrificed as clean controls (Normal group).   
The mice lungs were removed and immersed in fixative before being processed by 
dehydration and embedment in paraffin wax. Sections of 5µm in thickness were 
sliced and stained with hematoxylin and eosin (H & E) and visualized under light 
microscopy.   
The sections were examined qualitatively for lung injury (destruction of normal 
alveolar pattern and infiltration of immune cells into airway and alveoli) and 
compared with samples from the Normal group. The sections were also analyzed via 
with software Image-Pro Plus 6.3 to quantify the inflammatory factor of the samples. 
Inflammatory factor refer to a semi-quantitative measurement of the extent of alveolar 
walls thickening in the respective histology samples. Non-blinded measurements of 9 
random fields per group were performed and analyzed. The histology sections were 
analyzed with software Image-Pro Plus 6.3. The images generated by a microscope 
were connected to a camera and computer for offline processing. Using the software 
Image-Pro Plus 6.3, the area occupied by the thickened and distorted alveolar walls 
was quantitated by digital densitometry (Santos, et al., 2005). This would be 
proportional to the presence of edema and extent of inflammation in the lungs.   




3.6  Biochemical parameters  
3.6.1  Preparation of homogenates   
At 6 different time-points (Post-SM administration Day 1, 4, 7, 10, 14, and 21), 3 
mice from each respective group (Vehicle, SM Control and Treatment) were 
anesthetized via intraperitoneal injection of 0.4-0.6 mg/g Avertin and sacrificed. 3 
clean mice (no treatment administered) were also sacrificed as clean controls (Normal 
group).   
The lungs of the animals were removed, weighed and homogenized in 1:10 volume 
50mM potassium phosphate buffer, pH6.0, containing 0.5% 
hexadecyltrimethylammonium bromide (HTAB) in a Potter homogenizer (B.Braun). 
HTAB was used to solubilise the myeloperoxidase enzyme with high extraction 
efficiency (Bradley et al., 1982). Lungs were homogenized for 2min at 1500 
revolutions per min (rpm) and homogenates obtained were subjected to three freeze-
thaw cycles. Samples were then centrifuged at 14000rpm for 30min at 4ºC (Beckman 
Coulter). The supernatant was subsequently collected for protein quantification and 
myeloperoxidase assay.  
3.6.2  Protein measurements  
Protein quantification was conducted using Lowry Protein assay kit (Bio-Rad). 5µl of 
protein standards (bovine serum albumin, Sigma) or homogenate sample, 25µl 




Reagent A and 200µl Reagent B were added into each well of a 96-well plate. After 
15min incubation, the end-point absorbance at 595nm was determined for the 
resultant mixture. The protein concentration of each sample of homogenate was 
measured.  
3.6.3  Myeloperoxidase (MPO) assay  
MPO activity was used as a quantitative indicator of neutrophil infiltration (Mullane, 
et al., 1985). MPO assay was carried out using Pierce TMB Substrate Kit. 100µl of 
the TMB Substrate Solution was added to 25µl lungs supernatant and the change in 
absorbance at 655nm was measured kinetically. 1 unit of MPO activity is defined as 
the change in absorbance per minute caused by one gram of soluble protein. The 
average MPO value was then obtained for each group (Normal, Vehicle, SM Control 
and Treatment).    
3.7  Statistical analysis  
The statistical analysis was carried using Graphpad Prism 4.0. One way analysis of 
variance (ANOVA) was used to detect significant differences between groups. P 
values <0.05 would be considered significant.    




3.8  Effect of angiotensin IV, in combination treatment with either Divalinal 
ANG-IV or Losartan  
Mice were each intranasally inoculated with a single dose of 0.006mg/mouse SM and 
treated with 150 nmole/kg/day ANG-IV, together with either losartan (170 or 340 
nmole/kg/day) or divalinal ANG-IV (300 nmole/kg/day). At 300 nmole/kg/day, 
divalinal angiotensin IV, an AT4 receptor antagonist, had no effect on blood glucose. 
The selected doses of losartan, an AT1 receptor antagonist, were found to be 
ineffective in improving survival rate of SM intoxicated animals.  
The mice were given 0.1mL of each respective drug 60min before SM administration 
(pretreatment). SM LD80 was administered intranasally to each mouse, as described in 
the paragraph 3.3. 0.1mL of each of the respective drugs were given daily for 14 days, 
beginning with post-SM administration Day 1. ANG-IV was fed orally while 
divalinal ANG-IV and losartan were injected i.p. The vehicle group was intranasally 
administered with 50% ethanol while SM LD80 group was intranasally administered 
with 0.006mg SM with no treatment given.   
The weight and mortality of the animals were monitored daily for 21 days post-SM 
administration. The percentage of surviving mice in each group was reported at Day 
21 post-SM administration.      
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Chapter 4  Results 
4.1  SM lethal dose-response relationship in mice by intranasal challenge 
route  
It has been reported that in SM intoxication cases, most fatalities were often due to 
SM-induced pulmonary damages (Papirmeister, et al., 1991). SM exposure also led to 
persistent and clinically significant chronic lung diseases.   
Figure 1a showed the percentage survival rate of mice intoxicated with different SM 
concentration, reported at Day 21 post-SM administration. Figure 1b showed the 
lethal dose response plot of SM in mice by intranasal challenge route, where mortality 
was reported at Day 21 post-SM administration.   
Figure 1c showed the profile of weight loss in mice intoxicated with a single dose of 
LD80 SM concentration, reported over a period of 21 days post-SM. Figure 1d 
showed the survival profile of mice intoxicated with a single dose of LD80 SM 
concentration, reported over a period of 21 days post-SM.   
In the SM intranasal challenge, it was observed that increasing SM concentration 
resulted in proportionally higher percentage mortality of mice (Figure 1a). When the 
toxicology dose response plot was tabulated, a typical sigmoid dose response graph 
was observed (Figure 1b). The No Observable Effect Level (NOEL) was observed to 





>0.0075mg/mouse. The small standard error of the mean (SEM) observed in the 
repeated experiments showed comparable reproducibility of mice mortality for this 
SM intranasal challenge model.   
LD80 was found to be approximately 0.006mg/mouse SM, indicating that for every 10 
mice administered intranasally with 0.006mg/mouse SM, approximately 2 mice 
would be expected to survive till Day 21 post-SM. 0.006mg/mouse was selected as 
the SM concentration for subsequent drug dose ranging studies using the intranasal 
model.   
When the weight loss profile of the mice intoxicated with LD80 SM was noted over 21 
days (Figure 1c), it was observed that the mean weight of the mice decreased steadily 
after SM administration, with a maximum weight lost reported at around Day 10-11. 
Due to the considerable loss of body weight, the mice generally appeared emaciated. 
At Day 21, the mean weight of the surviving mice was approximately 80% of the 
original mean weight (at Day 0).   
When the percentage survival profile of the mice intoxicated with LD80 SM was noted 
over 21 days (Figure 1d), it was observed that the survival rate of mice was constant 
from Day 0 to Day 10 and decreased sharply after Day 10 (high death rate) before 



























Figure 1a. Percentage survival of mice intranasally inoculated with different doses of 
SM.   
Each SM dose was administered intranasally to a group of 10 mice (n=1), with the exception 
of 0.006mg and 0.01mg dose, where n=3 and 0.005mg dose, where n=2. The percentage of 
surviving mice in each group was reported at Day 21 post-SM administration. Intranasal 
protocol was described in Section 3: Materials and Methods. Significance between groups 
was assessed by one way ANOVA, utilizing Tukey test. * Significantly different from the 
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Figure 1b. Lethal dose response plot of SM in mice by intranasal challenge route   
(Percentage mortality reported at Day 21 post-SM).   
The percentage survival data of mice intoxicated with different SM concentrations (from 
Figure 1a) was represented as the percentage mortality over the different log [SM dose] to 
determine the lethal dose response profile of SM in mice. Percentage mortality of mice was 
























Figure 1c. Weight profile of mice intoxicated with LD80 SM concentration over a period 
of 21 days.   
A single dose of 0.006mg/mouse SM dose was administered intranasally to 3 groups of 10 
mice (n=3) and the average weight of all the animals were measured over a period of 21 days. 


























Figure 1d. Percentage survival profile of mice intoxicated with LD80 SM concentration 
over a period of 21 days.   
A single dose of 0.006mg/mouse SM dose was administered intranasally to 3 groups of 10 
mice (n=3) and the percentage survival of the mice were recorded over a period of 21 days. 





4.2 Dose Ranging studies: Treatment effects of ANG-IV, DAA-1 and 
Losartan respectively, on the percentage survival of LD80 SM intoxicated 
mice   
Angiotensin II was found to be one of the potential upstream proinflammatory 
mediators in the development of pulmonary damage and fibrosis (Song, et al., 1998, 
Dagenais, et al., 2005 and Wang, et al., 1999). We were interested in investigating if 
interrupting the angiotensin II inflammatory pathway with different compounds, 
ANG-IV, DAA-1 and Losartan (Loufrani, et al., 1999, Ng, 2007, and Marshall, 2003, 
respectively), known to have an effect on the angiotensin II proinflammatory 
pathway, could affect the survival rate of SM-intoxicated mice. Thus these 3 different 
compounds were selected for subsequent dose-ranging analysis to determine the 
optimum compound (and treatment dose) required.   
Figures 2a, 2b and 2c showed the percentage survival rate of SM-intoxicated mice 
treated with different doses of ANG-IV, DAA-1 and Losartan, respectively. Mice 
were the given respective treatment 1 hour before being intranasally intoxicated with 
a single dose of LD80 SM. Each respective treatment was continued daily for 14 days. 
Surviving mice numbers were reported at Day 21 post-SM.  
Results from dose ranging studies of ANG-IV, DAA-1 and Losartan (Figures 2a, 2b 
and 2c, respectively) revealed that the optimum effective dose for each treatment (in 
attenuating mortality rate) was 150 nmole/kg/day ANG-IV, 150 nmole/kg/day DAA-





compounds tested, 150 nmole/kg/day ANG-IV and 150 nmole/kg/day DAA-1, are 
angiotensin peptides, were found to be most effective in increasing the survival rate 
with current therapeutic strategy of pretreatment dose (1 hour before SM exposure) 
and daily treatment dose for 14 days post-SM administration.  
A biphasic dose response has been described as a response with 2 distinct phases, i.e. 
in dose response studies where treatment doses higher than the maximum effective 
dose were observed to be progressively inactive (Wen, et al., 2004 and Sim, et al., 
2007). The biphasic dose response has also been indicative of the phenomenon of 
hormesis, characterized when drug doses higher than the optimum efficacious dose 
become less efficacious (Calabrese, 2002).   
Thus, in this project, the dose response of ANG-IV and DAA-1 was described as 
biphasic as when the treatment dose administered was higher than the optimum 
effective treatment dose, the compound became less efficacious in attenuating 
mortality.   
This biphasic dose response was also noted in previous work involving DAA-1 
treatment of mice subjected to intranasal intoxication of CEES, a less toxic analogue 
of SM (Ng, 2007). It was observed that treatment with 75 nm/kg/day DAA-1 was able 
to significantly attenuate the weight loss and mortality in CEES-exposed mice and 
DAA-1 doses higher or lower than this effective dose were not as efficacious in 





As treatment with both ANG-IV and DAA-1 were able to reduce mortality rates of 
SM-intoxicated animals, these two compounds and their corresponding efficacious 










































Figure 2a. Percentage of survival of mice intoxicated with a single dose LD80 SM and 
treated with different doses of ANG-IV (with pretreatment and daily for 14 days post-
SM).   
6 groups of 10 mice were each intranasally inoculated with a single dose of 0.006mg/mouse 
SM and orally fed with 6 different doses of ANG-IV (37.5, 75, 150, 300, 450, 600 nm/kg/day 
dissolved in 0.1mL water). ANG-IV was given 1 hour before SM administration and daily for 
14 days post SM administration. Percentage of surviving mice in each group was reported at 
Day 21 post-SM administration. The vehicle group (n=3) was intranasally administered with 
50% Ethanol while SM LD80 group (n=3) was intranasally administered with 0.006mg SM 
without treatment given. Intranasal and treatment protocols were described in Section 3: 
Materials and Methods. * Significantly different from the value of vehicle animals (P<0.001), 







































Figure 2b. Percentage survival of mice intoxicated with a single dose LD80 SM and 
treated with different doses of DAA-1 (with pretreatment and daily for 14 days post-
SM).   
5 groups of 10 mice were each intranasally inoculated with a single dose of 0.006mg/mouse 
SM and orally fed with 5 different doses of DAA-1 (37.5, 75, 150, 300, 600 nm/kg/day 
dissolved in 0.1mL water). DAA-1 was given 1 hour before SM administration and daily for 
14 days post SM administration. Percentage of surviving mice in each group was reported at 
Day 21 post-SM administration. The vehicle group (n=3) was intranasally administered with 
50% Ethanol while SM LD80 group (n=3) was intranasally administered with 0.006mg SM 
without treatment given. Intranasal and treatment protocols were described in Section 3: 
Materials and Methods. * Significantly different from the value of vehicle animals (P<0.001), 








































Figure 2c. Percentage survival of mice intoxicated with a single dose LD80 SM and 
treated with different doses of Losartan (with pretreatment and daily for 14 days post-
SM).   
5 groups of 10 mice were each intranasally inoculated with a single dose of 0.006mg/mouse 
SM and i.p. injected with 5 different concentrations of losartan (85, 170, 340, 680, 1300 
nmole/kg/day dissolved in 0.1mL water). Losartan was given 1 hour before SM 
administration and daily for 14 days post SM administration. Percentage of surviving mice in 
each group was reported at Day 21 post-SM administration. The vehicle group (n=3) was 
intranasally administered with 50% Ethanol while SM LD80 group (n=3) was intranasally 
administered with 0.006mg SM without treatment given. Intranasal and treatment protocols 
were described in Section 3: Materials and Methods. * Significantly different from the value 







4.3 Model Consistency studies: Survival rate of intoxicated SM mice 
subjected to optimum dose of each test compound (ANG-IV, DAA-1 and 
Losartan)  
For the earlier dose-ranging experiments, only 1 group of 10 mice (n=1) was studied 
for each treatment dose. Hence, the 3 optimum efficacious treatment doses of each 
compound (150 nmole/kg/day ANG-IV, 150 nmole/kg/day DAA-1 and 340 
nmole/kg/day Losartan) were repeated to determine the reproducibility of the survival 
data at 21 days post-SM (n=2). One of the major symptoms of SM poisoning was 
reported to be the decrease in body weight (Vijayaraghavan, et al., 2005). Hence, the 
weight profile of the mice (in the best two treatment groups, ANG-IV and DAA-1) 
was also compared to determine the effects of the different treatments on body 
weight.   
Figure 3a showed the reproducibility in survival rate of mice intoxicated with 
0.006mg/mouse SM and treated with ANG-IV, DAA-1 and Losartan, respectively, 
with pretreatment dose and daily dose for 14 days post-SM daily. 21 days post-SM 
survival rate was reported.   
Figure 3b showed the corresponding percentage weight loss profiles (over 21 days 
post-SM) of LD80 SM control mice compared with LD80 SM intoxicated mice 
treated with ANG-IV or DAA-1, with pretreatment dose and daily dose for 14 days 





It was observed that most effective treatment was ANG-IV, followed by DAA-1 and 
Losartan, with approximately 80%, 60% and 20% survival rate respectively (Figure 
3a). Hence, the two best drugs at optimum dose were 150 nmole/kg/day ANG-IV and 
150 nmole/kg/day DAA-1.   
The profile of percentage weight loss over 21 days for SM control, ANG-IV and 
DAA-1 treatment mice were compared (Figure 3b). It was observed that in general, 
the percentage weight loss profiles of all three groups of mice increased steadily from 
Day 1 onwards to maximum weight loss at about Day 11. SM Control mice had the 
highest maximum percentage weight loss (>35%), followed by mice with DAA-1 
treatment (~30% maximum weight loss), and mice with ANG-IV treatment (~25% 
maximum weight loss). It was noted the treatment (ANG-IV) that resulted in the 
highest survival rate also has the lowest maximum weight loss, indicating a possible 


































Figure 3a. Model Consistency studies: Survival rate of mice intoxicated with SM and 
treated with maximum efficacious dose of ANG-IV, DAA-1 and Losartan, respectively 
(with pretreatment and daily for 14 days post-SM).   
60 mice were each intranasally inoculated with a single dose of 0.006mg/mouse SM and 
treated with either 150 nmole/kg/day DAA-1 (20 mice, n=2) or 150 nmole/kg/day ANG-IV 
(20 mice, n=2) or 340 nmole/kg/day losartan (20 mice, n=2). The respective treatment 
compounds were given 1 hour before SM administration and daily for 14 days post SM 
administration. Percentage of surviving mice in each group was reported at Day 21 post-SM 
administration. The vehicle group (n=3) was intranasally administered with 50% ethanol 
while SM LD80 group (n=3) was intranasally administered with 0.006mg SM without 
treatment given. Intranasal and treatment protocols were described in Section 3: Materials 
and Methods. Significance between groups was assessed by one way ANOVA, utilizing 
Tukey test. * Significantly different from vehicle (P<0.001). ** Significantly different from 
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Figure 3b. Profile of percentage weight loss of SM Control mice compared with 
intoxicated mice treated with ANG-IV and DAA-1 (with pretreatment and daily for 14 
days post-SM), over 21 days.   
40 mice were each intranasally inoculated with a single dose of 0.006mg/mouse SM and 
treated with either 150 nmole/kg/day DAA-1 (20 mice, n=2) or 150 nmole/kg/day ANG-IV 
(20 mice, n=2). The respective treatment compounds were given 1 hour before SM 
administration and daily for 14 days post SM administration. SM LD80 group (30 mice, n=3) 
was intranasally administered with 0.006mg SM without treatment given. Percentage of 
weight loss of the mice was measured over 21 days. Intranasal and treatment protocols were 





4.4 Effects of ANG-IV and DAA-1 treatment on lungs histopathology.  
It has been reported that SM-exposed mice displayed significant lung lesions, 
especially in the parenchyma regions where parenchymal debris, hemorrhagic 
exudates and edema have been observed (R. Vijayaraghavan, et al, 2005.). The two 
best treatment compounds at optimum dose (150 nmole/kg/day ANG-IV and 150 
nmole/kg/day DAA-1), from the previous dose ranging experiments, were selected 
for histopathological studies. To assess the effects of ANG-IV and DAA-1 treatment 
in ameliorating pulmonary inflammatory injury, the histopathology of lung samples 
(from Normal, Vehicle, SM Control and two Treatment groups) were examined and 
compared at x200 magnification.  
Figure 4.1 showed the H&E lung histology samples of Normal, Vehicle, SM Control 
and Treated (ANG-IV and DAA-1) mice, sacrificed on Day 1, 10, 14 and 21 post-
SM. Figure 4.2 showed the respective inflammation factor measured from the 
respective histological samples.   
Normal (Figure 4.1A) and Vehicle Control (Figures 4.1B - E) lung samples showed 
distinctive alveolar honeycomb pattern with normal alveolar septa, pulmonary 
capillaries and alveoli with intact epithelium. This indicated that the 50% Ethanol 
present in the Vehicle Control did not result in any abnormality in the lungs.  
In contrast, histopathological observations of SM Control lung samples showed a 





region. There was significant progressive thickening of alveolar walls, indicating the 
presence of edema. Congestion, parenchymal debris and serious exudation were also 
observed. These observations were indicative of the presence of severe progressive 
inflammation in the lungs. The symptoms appeared as early as Day 1 post-SM 
(Figure 4.1F) and became progressively more serious, peaking on Day 14 (Figure 
4.1H).   
The lung samples on Day 14 revealed severe edema and dramatic loss of the regular 
alveolar network. This destruction of the critical alveolar network would seriously 
impair the uptake of oxygen as well as the decrease the ability for carbon dioxide 
elimination in the mice. As a result of the loss of regular alveolar patterns, the 
enlargement of alveolar air space could be observed in Day 21 lung samples (Figure 
4.1I).   
Lung histology samples of SM-intoxicated mice treated with ANG-IV (Figures 4.1J - 
M) and DAA-1 (Figures 4.1N - O), appeared to have generally reduced inflammation 
lesions compared to the SM Controls at each respective day. This indicated that 
treatment with both compounds provided some level of pulmonary protection from 
damages caused by SM poisoning. Although certain regions still showed signs of lung 
damage (indicated by the progressive thickening of alveolar walls from Day 1 to Day 
21), substantial regular alveolar honeycomb patterns could still be observed in the 
ANG-IV treated and DAA-1 treated mice histology samples (as compared to 





pulmonary air exchange function in the treated mice was not overly affected or 
compromised.   
Although, it appeared that lung inflammation of SM Control mice lessened in Day 21 
(Figure 4.1I) compared to Day 14 (Figure 4.1H), it must be noted these lung samples 
were from mice that survived 21 days and were perhaps somewhat not adversely 
affected by SM administration. Hence, though the inflammation appeared to have 
reduced from Day 21 compared to Day 14 in untreated SM Control mice, it may not 
be accurate to imply that the affected mice had managed to recover from 
inflammation without treatment. It was more likely that the mice that survived till 
Day 21 somehow did not respond to SM as severely as those mice that died at post-
SM Day 14.  
The increase in inflammation factor in the lung samples (from Normal, Vehicle, SM 
Control and two Treatment groups) over 21 days was also tabulated (Figure 4.2) for 
semi-quantitative analysis. Inflammatory factor refer to a semi-quantitative 
measurement of the extent of alveolar walls thickening in the respective histology 
samples. These observations would correlate with the presence of severe progressive 
inflammation in the lungs. Non-blinded measurements of 9 random fields per group 
were performed and analyzed. The histology sections were analyzed with software 
Image-Pro Plus 6.3. The images generated by a microscope were connected to a 
camera and computer for offline processing. Using the software Image-Pro Plus 6.3, 





digital densitometry (Santos, et al., 2005).  This would enable a general semi-
quantitative comparison of the extent of thickened alveolar walls in the different 
treated and non-treated mice lungs samples.  
The results mirrored what was observed from the slides qualitatively. The 
inflammation factor was observed to increase steadily as early as Day 1 post-SM in 
all SM-exposed lung samples (Figure 4.2). On Day 14 post-SM, the inflammation 
factor peaked to a maximum in SM Control mice samples. This was also observed in 
the histology slides where the most severe alveolar wall thickening and lesion was 
observed in SM Control samples on Day 14 (Figure 4.1H). SM intoxicated mice 
treated with DAA-1 or ANG-IV have much lower inflammation factor 
(approximately 2-fold suppression), indicating that treatment with these compounds 
have effectively reduced the level of pulmonary inflammation present.   
As mentioned earlier, although it appeared that the inflammation factor of SM 
Control mice was reduced in Day 21 (Figure 4.2) without treatment, it must be noted 
these lung samples were from mice that survived 21 days and were perhaps somewhat 
not as adversely affected by SM administration, compared to mice that died at post-
SM Day 14. Hence, it cannot be concluded that the decrease of inflammation factor in 
untreated SM Control mice in Day 21 (as compared to Day 14) was due to the mice 







Figure 4.1. Lung histology of Normal (A), Vehicle Control (B-E), 
SM Control (F-I), 150 nmole/kg/day ANG-IV treated (J-M) and 
150 nmole/kg/day DAA-1 treated (N-O) mice, sacrificed on Day 1, 
10, 14 and 21. (Representative samples presented.)  
Green arrows indicate examples of alveolar wall thickening caused by 
edema. Pink arrows indicate examples of alveolar air space 
enlargement (loss of regular alveolar patterns). H&E staining. 200x.  
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Figure 4.2. Inflammation factor observed in histological slides: Vehicle, SM Control, 
150 nmole/kg/day ANG-IV and 150 nmole/kg/day DAA-1 treated mice. Mice sacrificed 
on Day 1, 4, 7, 10, 14, and 21.   
Mice were each intranasally inoculated with a single dose of 0.006mg/mouse SM and treated 
with either 150 nmole/kg/day ANG-IV or 150 nmole/kg/day DAA-1. The respective 
treatment compounds were given 1 hour before SM administration and daily for 14 days post 
SM administration. The vehicle group was intranasally administered with 50% Ethanol while 
SM LD80 group was intranasally administered with 0.006mg SM without treatment given. 3 
surviving animals (with the greatest loss of weight) from each group were sacrificed on Day 
1, 4, 7, 10, 14, and 21, respectively, and the lungs from each animal were processed for H&E 
staining and analyzed with software Image-Pro Plus 6.3 as described in Section 3: Materials 
and Methods. The inflammatory factor was measured by quantitating the area occupied by the 
thickened and distorted alveolar walls by digital densitometry. Each value represents the 
mean inflammatory factor +
 
SEM of 3 individual animals. Significance between groups was 
assessed by one way ANOVA, utilizing Tukey test. * Significantly different from SM LD80 







4.5  Effects of DAA-1 and ANG-IV treatment on lung MPO activity  
Neutrophil infiltration in lung tissues was quantitatively measured by the increase in 
MPO activity (Mullane, et al., 1985).  Influx of neutrophils has been reported to be 
directly correlated with the level of inflammation present at the injury site 
(Henderson, et al., 1993).   
Figure 5 showed the respective lung MPO activity from Normal, Vehicle, SM 
Control, ANG-IV treated and DAA-1 treated mice lung homogenates, sacrificed on 
Day 1, 4, 7, 10, 14, and 21, post SM.   
MPO activity of Vehicle Control increased 2.4-fold on Day 1 (with respect to MPO 
activity of Normal mice), but decreased steadily with time, such that by Day 14, MPO 
levels in Vehicle Control were similar to that of Normal mice (Figure 5).   
In contrast, MPO activity of SM administered mice increased slowly from Day 1 to 4 
before decreasing slightly on Day 7 and increasing significantly again from Day 10 
(3.1 fold increase) and Day 14 (4.1 fold increase).    
The MPO levels from both ANG-IV and DAA-1 treated samples did not show a 
significant difference from SM Control from Day 1 to Day 10, suggesting that the 
neutrophil infiltration had not been significantly affected.  However, the 
administration of ANG-IV and DAA-1 treatments significantly attenuated neutrophil 





fold suppression of MPO activity in the both Treated groups as compared to SM 
Control group.   
On Day 21, MPO levels between all the groups were not significantly different from 
the Vehicle Control, indicating that a reduction of pulmonary inflammation in SM 
Control and Treated mice. Although, it appeared that MPO levels of SM Control mice 
were reduced in Day 21 post-SM, it must be noted these lung samples were from 
mice that survived and were somewhat not adversely affected by SM administration 
(similar to Histology data). Hence, it may not be accurate to propose that since MPO 
levels decreased in untreated SM Control mice, they had managed to recover from 
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Figure 5. Lung MPO activity of Normal, Vehicle control, SM Control, 150 nmole/kg/day 
ANG IV treated and 150 nmole/kg/day DAA-1 treated mice, sacrificed on Day 1, 4, 7, 
10, 14, and 21.   
Mice were each intranasally inoculated with a single dose of 0.006mg/mouse SM and treated 
with either 150 nmole/kg/day ANG-IV or 150 nmole/kg/day DAA-1. The respective 
treatment compounds were given 1 hour before SM administration and daily for 14 days post 
SM administration. The vehicle group was intranasally administered with 50% ethanol while 
SM LD80 group was intranasally administered with 0.006mg SM without treatment given. 3 
surviving animals (with the greatest loss of weight) from each group were sacrificed on Day 
1, 4, 7, 10, 14, and 21, respectively, and the lungs from each animal were homogenized for 
MPO analysis. MPO analysis protocol was described in Section 3: Materials and Methods. 
Each value represents normalized MPO mean +
 
SEM of 3 individual animals. Significance 
between all groups was assessed by one way ANOVA, utilizing Tukey test. * Significantly 
different from the value of vehicle animals (P<0.05). ** Significantly different from the value 





4.6 Effect of angiotensin IV, in combination treatment with either Divalinal 
ANG-IV or Losartan, on survival of SM LD80 intoxicated mice  
From this study, ANG-IV has been demonstrated to be most effective in increasing 
the survival rate of SM-intoxicated animals and reducing the pulmonary inflammation 
caused by SM. However, the mechanism pathways by which ANG-IV mitigates 
inflammation have not been determined. ANG-IV have been found to bind with high 
affinity, selectively and reversibly to AT4 receptor binding site, identified as insulin-
regulated aminopeptidase (IRAP) (Caron, et al., 2003 and Ruiz-Ortega, et al., 2007). 
The presence of AT4 specific binding sites have been found in various tissues, 
including lungs, kidneys, heart and blood vessels (Hamilton, et al, 2001 and Thomas, 
et al., 2003). Studies have also noted that ANG-IV-induced reductions in renal artery 
blood flow were blocked by Losartan, suggesting mediation by AT1 receptors 
(Gariner, et al., 1993 and Fitzgerald, et al., 1999).    
Thus, in the subsequent experiment, divalinal angiotensin IV, an AT4 receptor 
antagonist and losartan, an AT1 receptor antagonist, were separately co-administered 
together with ANG-IV and the survival rate of the treated mice observed to determine 
if the AT4 or AT1 receptors, respectively, were involved in the increased survival rate 
of ANG-IV treated SM-intoxicated mice. The doses of losartan selected were earlier 
found to be ineffective in improving survival rate of SM intoxicated animals.  
Figure 6 showed the survival rate of SM-exposed mice treated with 150 





nmole/kg/day) or losartan (170 nmole/kg/day or 340 nmole/kg/day), with 
pretreatment dose and daily treatment dose for 14 days post-SM. The survival rate of 
each group was reported at Day 21 post-SM.  
It was observed that the survival rates of SM intoxicated mice treated with the 
combination of 150 nmole/kg/day Angiotensin IV, with divalinal ANG-IV or 2 doses 
of losartan (170 nmole/kg/day or 340 nmole/kg/day) were lower than that of ANG-IV 
treated mice (Figure 6).   
When ANG-IV treatment was administered alone, there was an approximate 70% 
survival rate. However, with the co-administration of divalinal ANG-IV or losartan, 
the survival rate decreased to 0% and approximately 10%, respectively, indicating 
that both divalinal ANG-IV and losartan have antagonized the protective effects of 
ANG-IV in SM intoxicated mice.   
As divalinal ANG-IV and losartan were specific AT4 and AT1 receptor blockers 
respectively, the data indicated that ANG-IV exerted its protective action via both the 
AT4 and AT1 receptors. However, more investigations would be required to study the 

































Figure 6. Percentage survival rate of mice intoxicated with SM and treated with 2 
treatment compounds: 150 nmole/kg/day ANG-IV, in combination with either Losartan 
or Divalinal ANG-IV (with pretreatment and daily for 14 days post-SM).  
3 groups of 10 mice were each intranasally inoculated with a single dose of 0.006mg/mouse 
SM and treated with 150 nmole/kg/day ANG-IV, together with either losartan (170 or 340 
nmole/kg/day) or divalinal ANG-IV (300 nmole/kg/day). The doses of losartan selected were 
earlier found to be ineffective in improving survival rate of SM intoxicated animals. At 300 
nmole/kg/day, divalinal angiotensin IV had no effect on blood glucose. The mice in 
SM+ANG-IV group were solely treated with 150 nmole/kg/day ANG-IV. The respective 
treatment compounds were given 1 hour before SM administration and daily for 14 days post 
SM administration. ANG-IV was fed orally while divalinal ANG-IV and losartan were 
injected i.p. The vehicle group was intranasally administered with 50% Ethanol while SM 
LD80 group was intranasally administered with 0.006mg SM without treatment given. 
Percentage of surviving mice in each group was reported at Day 21 post-SM administration. 
Intranasal and treatment protocols were described in Section 3: Materials and Methods. 
Significance between groups was assessed by one way ANOVA, utilizing Tukey test. * 
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Chapter 5  Discussion 
Sulfur mustard is an alkylating agent with cytotoxic, mutagenic and vesicating 
properties. Despite almost 50 years of research, the mechanism of SM toxicity has not 
been completely described and thus, an effective antidote has not been developed 
(Papirmeister, et al., 1991). While sulphur mustard induced damages to skin could be 
treated by aggressive debridement and skin transplants, there is no known medical 
countermeasure (pretreatment or therapy) for SM induced respiratory and eye injuries 
(Eisenmenger, et al., 1991 and Lakshmana, et al., 1999).   
Although the significance of inflammation to SM pathology has not been established, 
recent studies have indicated that inflammation play a primary role in cutaneous 
vesication after exposure to SM. The role of inflammation in the pathogenesis of SM 
skin lesion may involve complex dynamic interactions of a cascade of 
proinflammatory mediators (Cowan, et al., 1993). Hairless guinea pigs exposed to 
SM showed infiltration of neutrophils at lesion sites as early as 3hrs post exposure 
and a concurrent elevation of myeloperoxidase, a neutrophil-associated enzyme, was 
also observed (Cowan, et al., 1993).   
In vitro studies with nitrogen mustard melphalan, an alkylating agent like SM, have 
also demonstrated the activation of a proinflammatory response very early in 
melphalan exposure (Osterlund, et al., 2005). In fact, the upregulation of stress-





5 minutes post-melphalan exposure with the translocation of nuclear factor (NF)-kB 
into the cell nuclei within 45 minutes. Within 2 hours, elevated levels of TNF- were 
also observed. In addition, angiotensin II was also found to be one of the potential 
upstream proinflammatory mediators in the development of pulmonary damage and 
fibrosis (Song, et al., 1998, Dagenais, et al., 2005 and Wang, et al., 1999).    
DAA-1, a bioactive angiotensin II peptide, was known to have an effect on the 
angiotensin II proinflammatory pathway. Studies have shown that DAA-1 treatment 
was able to increase survival numbers of mice intoxicated with 2-chlorethyl-ethyl 
sulfide (CEES), a less toxic analog of SM (Ng, 2007). DAA-1 treatment was also 
found to be effective in attenuating weight loss and alveolar cell damage in CEES-
exposed animals via downregulating inflammatory effects such as reducing neutrophil 
infiltration and ICAM-1 levels in the lungs of afflicted mice (Ng, 2007).    
Understanding and characterizing the inflammatory mechanisms involved SM-
induced pathogenesis could lead to the development of anti-inflammatory therapeutic 
compounds that may interrupt the damage caused by SM. Hence, the SM intranasal 
lung intoxication model was developed to study the survival rate, biochemical and 
histological indicators for SM-induced lung injury.   
This project aimed to complement the previous work (Ng, 2007) mentioned earlier 
and we were keen to investigate if interrupting the angiotensin II inflammatory 





mice and protect against SM-induced pulmonary biochemical and histopathological 
changes. ANG-IV, a short angiotensin peptide fragment obtained by degradation of 
angiotensin II and DAA-1, have been shown to effectively modify angiotensin II 
pathways (Loufrani, et al., 1999). DAA-1 and losartan were also investigated 
alongside ANG-IV treatment, to determine if they could improve the survival rate of 
SM-intoxicated mice and ameliorate SM-induced pulmonary biochemical and 
histopathological changes.    
5.1  SM lethal dose-response relationship in mice by intranasal challenge 
route  
The present study was designed to describe the biochemical and histopathological 
effects of intranasally administered SM in a chronic mouse model and hence the 
animals were monitored over a period of 21 days. The intranasal model was selected 
as it was a relatively fast and simple model that ensured SM would be administered 
directly into the lungs. The intranasal administration, coupled with anesthetic 
isofluorane inhalation, was found to be an effective and noninvasive technique for the 
delivery of substances to the respiratory tracts (Southam, et al., 2002). As SM was 
administered drop-wise directly into the lungs, this model would simulate lower 
respiratory tract exposure and damage.  
A typical lethal toxicology dose response sigmoid shape graph was observed (Figure 





0.006mg/mouse (for approximately 20g mouse). 0.006mg/mouse (LD80) was selected 
to be the SM dose for subsequent intranasal treatment studies as given its high 
toxicity, the biochemical and histopathological changes induced in mice would be 
significant. Any amelioration of these changes by the respective test compounds 
would also be readily and unambiguously determined.  
A progressive loss in body weight of mice intoxicated with SM LD80 was observed 
over time (Figure 1c). As the mice were given ad libitum access to food and water, 
the daily food intake of the animals was not recorded. However, general observations 
of the intoxicated animals revealed poor feeding and reduced fecal output, indicating 
a reduced food intake.   
This was expected as SM, being a radiomimetic compound would result in systemic 
toxicity and have an adverse effect on the general well being of the intoxicated 
animals, thus affecting their feeding patterns (Dacre, et al., 1996). In addition, SM-
intoxicated mice were observed to be less active. Hence, due to the considerable loss 
of body weight, the mice appeared emaciated. The reduction in body weight was 
observed as early as 24-hour post-SM exposure and the highest maximum weight loss 
occurred at about Day 10 to 11 post-SM. Other studies have also reported similar 
observations that SM-intoxicated animals were less active and showed lesser food and 





This progressive loss of body weight was a consistent observation in other studies 
involving SM intoxication and dose-dependent decrease in body weight following 
SM administration has been reported in rats and mice (Venkateswaran, et al., 1994, 
Kumar, et al., 2001 and Jafari, 2007).  However, the weight loss data reported in other 
papers often did not detail the weight loss profile over 21 days as they were more 
interested in acute pharmacological changes. Hence, the result from this chronic 
model were interesting as it revealed the large extent and persistent damage of SM 
intoxication such that even after 21 days post-SM, the mice that survived were still 
not able to return to their original pre-exposure weights (Figure 1c).   
It was noted that mice subjected to a similar intranasal model involving CEES (LD80) 
inoculation were able to regain their original weight approximately 14 days after post-
CEES intoxication with no treatment administered (Ng, 2007). By day 21 post 
exposure, surviving untreated CEES mice were actually heavier than their pre-CEES 
exposure weight, indicating that they had managed to recover without treatment. This 
indicated that although the lethal dose of the respective SM and CEES intoxication 
were similar (20% survival rate, LD80), the internal damage and injury caused by SM 
were more still severe and persistent than that caused by CEES, such that the 
surviving SM animals were not able to regain their original weight even after 21 days 
post SM exposure.   
In addition, it was interesting to note that the SM dose (0.006mg/mouse) administered 





1d). This correlated to the maximum weight loss observed at about Day 10 and 
suggested that the large weight loss induced by SM exposure could indirectly play a 
role in the overall survival rate.    
5.2  Treatment effects of ANG-IV, DAA-1 and Losartan, respectively, on the 
percentage survival rate of SM intoxicated mice.  
We were interested to determine if modulating the angiotensin II inflammatory 
pathway could improve the survival rate of SM-intoxicated mice. Hence, specific 
compounds, ANG-IV, DAA-1 and Losartan, known to have an effect on the 
angiotensin II proinflammatory pathway (Loufrani, et al., 1999, Ng, 2007, and 
Marshall, 2003, respectively), were selected in the subsequent studies.   
As SM was known to result in chronic inflammation in the lungs, it was necessary to 
subject the mice to a continuous daily treatment of the test compounds for 14 days to 
mitigate the inflammatory process and progression. After 14 days of treatment, a 
further 7 days of observation was conducted to ensure that the condition of SM-
intoxicated animals continued to improve and did not deteriorate without the presence 
of the treatment compounds. It was noted that the animals continued to gain weight 
after 14 days. Thus, the study endpoint was 21 days. There was no toxicity observed 
in the vehicle animals after 14 days of treatment with the test compounds.   





aldosterone system and found to be locally produced in the lungs. Angiotensin II is a 
proinflammatory mediator and the activation of AT1 receptors by angiotensin II were 
shown to result in (NF)-kB activation (Dagenais, et al., 2005). NF-kB activation have 
been demonstrated to promote the upregulation of various proinflammatory cytokines 
and adhesion molecules, including TNF- , IL-6 and IL-8, which were also found to 
be upregulated during SM exposure (Arroyo, et al., 2003,  Wormser, et al., 2005 and 
Emmler, et al., 2007). In addition, angiotensin II were found to downregulate 
peroxisome proliferators-activated receptors, which have anti-inflammatory effects 
(Tham, et al., 2002).   
ANG-IV and DAA-1 are bioactive angiotensin peptides and are metabolites of 
angiotensin I. They are both degradation peptides from angiotensin I (Figure A). It 
has been initially reported that ANG-IV caused both vasodilatation and 
vasoconstriction in rat but it was not determined whether ANG-IV was an exclusive 
agonist for AT4 receptor or a partial and active agonist for the AT1 receptor 
(Abrahamsen, et al., 2002). However recently, some studies have shown that at 
nanomolar concentrations, ANG-IV was able to upregulate mean arterial pressure and 
cause renal cortical effects by interacting with AT1 receptor-activated signaling (Li, et 
al., 2006). Binding assays have revealed that DAA-1 acts on the AT1 receptor, 
antagonizing the responses from angiotensin II (Woei-Shin, et al., 2002). In addition, 
the functional effects of DAA-1 were found to be abolished by the AT1-specific 





Losartan is an angiotensin II receptor blocker (ARB). ARBs are able to interrupt 
angiotensin II activity by antagonizing the AT1 receptor. In a bleomycin-induced lung 
injury in vivo model, administration of losartan resulted in attenuation of pulmonary 
angiotensin II expression and collagen deposition (Marshall, 2003).   
In the dose ranging studies using treatment of ANG-IV and DAA-1 on SM-exposed 
mice (Figures 2a and 2b, respectively), it was also observed that treatment with 150 
nmole/kg/day ANG-IV was most effective in increasing the survival rate of SM-
intoxicated mice (Figure 3a), followed by 150 nmole/kg/day DAA-1. ANG-IV 
treatment resulted in 70% survival rate compared to 20% survival rate of SM Control 
without treatment. DAA-1 treatment was also quite promising, with a 60% survival 
rate. Losartan treatment was found to be not effective in preventing death as its 
survival rate was similar to that of SM Control.   
It was also noted that the dose concentrations of ANG-IV and DAA-1 that were 
higher than the effective dose of 150 nmole/kg/day did not yield high survival rates. 
This revealed a biphasic dose response phenomenon, known as hormesis, which can 
be characterized when drug doses higher than the optimum efficacious dose were less 
efficacious (Calabrese, 2002). The biphasic nature of DAA-1 was similar to that 
reported in other papers (Ng, 2007 and Sim, et al., 2007). As mentioned previously, it 
was observed that treatment with 75 nm/kg/day DAA-1 was able to significantly 





higher or lower than this effective dose were not as efficacious in attenuating 
mortality in CEES-exposed mice (Ng, 2007).   
Although the mechanism for the hormesis effect was not known, it was suggested that 
effective doses of DAA-1 could possibly induce receptor downregulation by different 
pathways. Due to its non-specific action on the IP3 arm of the AT1 receptor, it was 
hypothesized that high doses of DAA-1 was able to mimic the destructive 
inflammatory action of angiotensin II (Ng, 2007).   
ANG-IV, an endogenous angiotensin peptide and a product of DAA-1 degradation, 
seemed to have comparable properties like DAA-1 as higher doses of ANG-IV 
exhibited similar inhibitory effects on survival of SM exposed mice. In vascular 
smooth muscle cells in vitro, it was reported that incubation with high levels of ANG 
IV was able to activate NF-kB pathway and increased the expression of 
proinflammatory genes (Esteban, et al. 2005). This could explain why higher doses of 
ANG-IV, like DAA-1, were less efficacious in attenuating mortality in SM exposed 
mice as higher doses of ANG-IV may trigger and sustain inflammation mechanisms, 
resulting in increased tissue and cellular damage.   
There was a progressive loss of body weight (over 21 days) for SM control, ANG-IV 
and DAA-1 treated mice (Figure 3b). Maximum weight loss for all groups was 
observed to be about Day 11. As expected, SM Control mice had the highest 





(~30% maximum weight loss), and then mice with ANG-IV treatment (~25% 
maximum weight loss). Surviving mice subjected to treatment in ANG-IV was also 
able to gain back to their original weight by Day 21 post-SM. ANG-IV was 
demonstrated to be more effective than DAA-1 in protecting the mice body weight 
reduction induced by SM. Hence, it may be possible that ANG-IV, an endogenous 
angiotensin metabolite of DAA-1, was the efficacious moiety of DAA-1.  
ANG-IV treatment which resulted in the highest survival rate also has the lowest 
maximum weight loss. Thus, there could be a possible correlation between survival 
and weight loss, though its precise mechanisms of action remain unclear. This 
protection of SM-induced body weight reduction may be due to the proposed anti-
inflammatory properties of ANG-IV and would be further elaborated in the following 
sections.   
It was interesting to note that an earlier study has shown that administration of trolox 
(water soluble analogue of vitamin E) and quercetin (flavonoid) as a therapeutic 
intervention, was also able to protect the body weight loss of mice following SM 
inhalation exposure (Kumar, et al., 2001). The treatments were administered three 
times; one immediately after SM exposure, and once each day for two days post-SM. 
Trolox and quercetin have antioxidants and free radical scavenging properties which 
may play a role in attenuating SM-induced inflammatory damages. Reactive oxygen 
species were found to be upregulated in SM-induced lesion and free radical 





able to reduce the activation of inflammatory mediators.    
5.3  Effects of DAA-1 and ANG-IV on SM-induced lung histopathology  
Due to its vesicative effects, SM exposure results in considerable tissue injury, which 
in turns lead to severe and sustained inflammation. Significant increase in total 
protein levels have been observed in bronchoalveolar lavage fluid and albumin from 
rats subjected to SM inhalation studies, indicating of a compromise of the 
alveolar/capillary barrier (Anderson, et al., 2000). Infusion of angiotensin II have 
been shown to produce pulmonary edema and influence microvascular permeability 
in a rabbit model (Takatsugu, et al., 2007).   
The severity of the pulmonary model can be seen with SM-exposed lungs showing a 
progressive development of inflammatory lesions and edema, resulting in alveolar 
wall thickening as early as 1 day post-SM exposure. By visual observation at x200 
magnificaton, the damage in SM-exposed lungs was most severe on Day 14 post-SM 
exposure and this was supported as the inflammatory factor recorded on Day 14 was 
also the highest (Figure 4.2).   
As lung myeloperoxidase (MPO) activity was also concurrently analyzed and 
reported in this project, specific staining and counting of neutrophils in histology 
slides were not performed. This was because the results obtained from the MPO assay 





show the extent of neutrophil infiltration in the lung tissues, thus indicating the 
severity of inflammation in the different test groups (to be further elaborated in 
Section 5.4). In addition, tissue myeloperoxidase (MPO) activity has been widely 
considered to be a quantitative indicator of neutrophil infiltration (Mullane, et al., 
1985).  
These observations revealed similarities to a recently established in vitro model of the 
human blood-air barrier, where the alveolar-type co-cultures exposed to SM showed a 
reduction of barrier functionality, enhanced degree of nuclear DNA fragmentation 
and stimulation of proinflammatory markers (IL-6 and IL-8) (Emmler,  et al., 2007).  
The data may also explain why the death rate of SM-exposed mice increased sharply 
from Day 10 onwards (Figure 1d) as such severe impairment of the alveolo-capillary 
barrier would lead to a compromised gas-exchange and have a serious effect on the 
ability of the animals to survive (Figures 4.1G and Figures 4.1H). The loss of 
elasticity in the lung and the thickening of alveolar walls would also obstruct the 
gaseous exchange function in these untreated animals, leading to breathing difficulty. 
In past incidents involving SM attacks, death in victims was usually attributed to 
respiratory failure (Borak, et al., 1992).  
In addition to the acute effects of SM exposure, it was found that even 21 days post-
SM exposure, mice lungs still displayed inflammatory lesions and loss of alveolar 





inflammation (Figure 4.1I). Damages and lesions to the lungs tissues were 
irreversible. In fact, this long-term effect of SM exposure could also be observed 
more dramatically in human victims. In a study of Iranian soldiers exposed to a single 
large dose of SM, it was found that 20 years after the initial exposure, victims were 
still suffering from ongoing severe chronic inflammatory respiratory disorders and 
pulmonary fibrosis (Shohrati, et al., 2008). These victims were found to have 
increased levels of CD4 T-cells and inflammatory mediators in the bronchoalveolar 
lavage fluid, suggesting that ongoing inflammation was still intense in SM-induced 
bronchiectasis even after 20 years post-SM exposure. (Emad, et al., 2007).  
The treatment using efficacious doses of 150 nmole/kg/day ANG-IV (Figures 4.1J-
M) and 150 nmole/kg/day DAA-1 (Figures 4N-O) proved effective in attenuating 
SM-induced lung injury in this model. Although there were some indications of 
developing pulmonary inflammation (revealed by areas of progressively thickened 
alveolar walls) in samples post-SM Day 1 to Day 21, substantial normal alveolar 
honeycomb patterns could still be observed in the ANG-IV treated and DAA-1 
treated mice histology samples as compared to the untreated SM Controls. In 
particular, samples from the treated animals post-SM Day 10 onwards showed 
significant protection in their pulmonary alveolar structure compared to untreated 
animals. A good portion of the regular alveolar honeycomb structure was preserved in 





This was also reflected in the inflammation factor data where from post-SM Day 10 
onwards, the treated animals had considerably low inflammation factor comparable to 
SM control animals (Figure 4.2). The decrease in inflammatory factor in both ANG-
IV treated and DAA-1 treated samples was most remarkable on Day 14, where almost 
slightly less than two-fold reduction in inflammatory factor was recorded.   
Treatment with either ANG-IV or DAA-1 prevented SM-induced morphological 
changes in the lungs and reduced the level of inflammation stimulated by SM 
damage. In vitro studies have shown that ANG-IV was able to induce lung 
endothelial cell proliferation via activating DNA synthesis and triggering multiple 
signaling molecules (Li, et al., 2002). ANG-IV have also been shown to play an 
important role in the regulation of translational signaling in lung endothelial cells, via 
increasing the phosphorylation of eukaryotic initiation factor 4E binding protein 1 
(involved in RNA translation, cell growth and protein synthesis) (Lu, et al., 2005). 
This may explain the protective effects observed in the lung histology samples of SM 
exposed mice treated with ANG-IV.   
The ability of DAA-1 in suppressing inflammation could be seen in a rat myocardial 
infarction model, where DAA-1 was able to downregulate inflammation by 
suppressing proinflammatory cytokines and immune cells (macrophages and 
monocytes) infiltration (Rufaihah, et al., 2006). Treatment with DAA-1 was also able 
to protect against lungs damage in mice exposed to CEES (Ng, 2007). Thus, it was 





demonstrated effectiveness in attenuating the inflammatory pathways involved in SM 
lung injury.  
Although it appeared that lung inflammation of SM-intoxicated mice (treated or 
untreated) was lower in Day 21 compared to Day 14 (Figure 4.2), it must be noted 
the lung samples were from mice that survived post-SM 21 days and were somewhat 
not adversely affected by SM exposure. Hence, though the inflammation factor 
appeared to have reduced from Day 21 compared to Day 14 in untreated SM mice, it 
may not be accurate to imply that the affected mice had managed to recover from 
inflammation without treatment. It was more likely that the mice that survived till 
Day 21 somehow did not respond to SM as severely as those mice that died at post-
SM Day 14. Hence, lungs samples of these mice might not display adversely 
reactions to SM compared to the mice that did not survive.   
5.4  Effects of DAA-1 and ANG-IV on lung MPO activity  
Tissue myeloperoxidase (MPO) activity was used as a quantitative indicator of 
neutrophil infiltration (Mullane, et al., 1985). The influx of neutrophils to tissue 
injury sites was reported to be an indicator of inflammation (Henderson, et al., 1993). 
Neutrophils produced reactive oxidative species (ROS) via an oxygen dependent 
pathway. Under normal physiological conditions, the production of ROS by 
neutrophils would be beneficial as it would destroy pathogens and prevent their 





injury site, the inherent oxidative nature of neutrophilic ROS would then result in 
oxidative stress and cause further damage to the injury site. In a rat model experiment 
using CEES, significant attenuation of pulmonary injury have been observed with 
depletion of neutrophils or complement prior to intratracheal administration of CEES 
(McClintock, et al., 2002).  
The MPO activity of SM exposed mice increased progressively from Day 1 post-SM 
exposure, peaking at Day 14 (Figure 5). Together with the histological data, these 
findings have indicated that following a single exposure to SM, there was a 
significant and progressive increase in neutrophil infiltration into the lung tissue over 
time, enhancing and sustaining ongoing inflammation at the injury site. The 
progressive inflammation was observed to peak at post-SM Day 14. The data may 
also explain why the death rate of SM-exposed mice increased sharply from Day 10 
onwards (Figure 1d) as such severe increase of inflammation present in the animals 
may have a serious effect on their ability to survive. In fact, studies have shown that 
the influx of neutrophils activated alveolar macrophages and increased cytokine 
production, further exacerbating the degree of lung inflammation and the continued 
generation of ROS at the injury site (Grattendick, et al., 2002).  
Although MPO levels from both ANG-IV and DAA-1 treated samples did not show a 
significant difference from SM Control samples post-SM Day 1 to Day 10, there was 
a significant suppression of MPO activity in both treated groups (ANG-IV and DAA-





highest. Thus, the data indicated that ANG-IV and DAA-1 treatments were able to 
mediate the downregulation of neutrophil influx to the injury site. This 
downregulation of neutrophils would thus result in reduced pulmonary inflammation 
and in turn, lessened the aggravation of lung tissue damage in the SM exposed mice.   
A concurrent study in our lab also showed a progressive increase in T1-
 
in 
bronchoalveolar lavage fluid of mice subjected to intranasal administration of SM 
(unpublished data). The bronchoalveolar lavage fluid was collected at different time 
intervals post-SM exposure. Bronchoalveolar lavage was an effective method used to 
monitor the extent of pulmonary damage directly in the airway and alveoli 
(Henderson, 1989). T1- , a pro-inflammatory mediator, peaked at Day 7 post-SM 
exposure, and was suppressed with treatment by ANG-IV or DAA-1.   
Taken together, the results from these studies suggested that the mechanisms by 
which ANG-IV and DAA-1 treatment increased survival rate of SM-exposed mice 
and ameliorated SM-induced pulmonary injury may be related to attenuating the 
inflammation level at the injury site. SM-intoxicated mice treated with either ANG-
IV or DAA-1 showed dramatic suppression of pulmonary edema and parenchymal 
damage and a concurrent reduction in neutrophil influx (reduced MPO activity). With 
lower levels of inflammation, oxidative and cellular stress at the damaged lung tissues 





Although the precise mechanisms for RAS inhibition has not been determined, both 
ANG-IV and DAA-1 play a role in influencing the angiotensin II pathway. Hence, 
our study suggested that in a mouse model, SM-induced pulmonary damages and 
death can be reduced via mediation of the angiotensin II pathway.   
5.5  Effect of angiotensin IV, in combination treatment with either Divalinal 
ANG-IV or Losartan, on survival of SM LD80 intoxicated mice  
With the co-administration of divalinal ANG-IV or losartan, the survival rate of the 
SM exposed mice decreased to 0% and approximately 10%, respectively, indicating 
that both divalinal ANG-IV and losartan have antagonized the protective effects of 
ANG-IV in SM intoxicated mice (Figure 6). When ANG-IV treatment was 
administered alone, there was an approximate 70% survival rate. As divalinal ANG-
IV and losartan were specific AT4 and AT1 receptor blockers respectively, the data 
indicated that ANG-IV exerted its protective action via both the AT4 and AT1 
receptors.   
ANG-IV have been found to bind with high affinity, selectively and reversibly to AT4 
receptor binding site, identified as insulin-regulated aminopeptidase (IRAP) (Caron, 
et al., 2003 and Ruiz-Ortega, et al., 2007). The presence of AT4 specific binding sites 
have been found in various tissues, including lungs, kidneys, heart and blood vessels 





express IRAP, with ANG-IV specific binding sites and enzymatic activity (Esteban, 
et al., 2005).   
IRAP, a type II integral membrane protein, colocalizes with the insulin-responsive 
glucose transporter GLUT4 in the intracellular membrane vesicles (Keller, 2004). The 
translocation of IRAP and GLUT4 to the plasma membrane occurs in the presence of 
insulin. Although there has been no conclusive evidence detailing the mechanism by 
which ANG-IV interacts with IRAP (AT4 receptor) to bring about its protective anti-
inflammatory effects, three possible hypotheses have been proposed to explain the 
outcome of interaction between ANG-IV and IRAP (Stragier, et al., 2008). These 
include, the inhibition of the aminopeptidase activity of IRAP by ANG-IV, the 
interference of the translocation of IRAP and GLUT4 and the activation of 
intracellular signaling via receptor binding of ANG-IV to IRAP. The inhibition of the 
aminopeptidase activity IRAP by ANG-IV may result in the accumulation of 
substrates which may mediate a possibly anti-inflammatory effect via the 
upregulation of specific pathways. ANG-IV has also been demonstrated to induce 
cellular proliferation of cultured cells, such as rat fibroblasts, via the AT4 receptor 
(Brown, et al., 1998).   
Decreased expression of GLUT4 was found in IRAP knockout mice, supporting the 
hypothesis that the translocation of IRAP and GLUT4 may be impaired in type 2 
diabetes patients (Keller, 2004). The ability of ANG-IV to bind to IRAP may possibly 





surface (Stragier, et al., 2008). The consequent increased glucose uptake may be 
involved in the protective anti-inflammatory effect of ANG-IV treatment in 
promoting the survival of SM exposed mice.   
Studies in the brain have shown that ANG-IV is a competitive inhibitor, not a 
substrate of IRAP (Chai, et al., 2004). By inhibiting IRAP enzyme activity, ANG-IV 
would be able to prolong the presence of certain bioactive peptides in the tissues, thus 
mediating specific functional pathways. In addition, ANG-IV has also been shown to 
bind to IRAP as a receptor, activating intracellular signaling systems to bring about 
its effects. Signal transduction initiated by ligand binding to the C-terminal domain 
receptor of IRAP, would lead to interaction with cytoplasmic proteins in the 
intracellular domain (Vauquelin, et al., 2002).   
A significant increase of reactive oxygen species (ROS) was observed after SM 
exposure, suggesting ROS may be possible mediators of SM-induced toxicity (Ng, 
2007, Brimfield, et al., 2009 and Steinritz, et al., 2009). Inhibition of ROS formation 
resulted in a significant decrease of SM-induced apoptosis (Steinritz, et al., 2009). 
Interestingly, recent studies have shown mice with established atheroma that 
underwent two week treatment with ANG-IV demonstrated improvement in 
endothelial function, with a decrease in ROS such as superoxide production and an 
upregulation of endothelial nitric oxide synthase (eNOS) expression (Vinh, et al., 
2008). In addition, ANG-IV mediated increase in eNOS immunoreactivity was also 





upregulation of ROS, NO levels were lowered as NO was found to be rapidly 
scavenged.   
Atherosclerosis has been established as a chronic inflammatory cardiovascular 
disease. It has also been reported that in cardiovascular diseased state, disruption in 
the endothelium caused reduced bioavailability of nitric oxide (NO), enhancing 
inflammation (Gimbrone J. 1995). Hence, it was possible to postulate that ANG-IV 
mediated inflammation via the same mechanisms of ROS inhibition as observed in 
mice inflammatory atherosclerosis model described earlier.   
AT4 receptor have been shown to be significantly elevated in injured rabbit carotid 
vessels within one week after lesion and further elevated at 20 weeks post injury 
(Moeller, et al., 1999). AT4 was also shown to play a role in vascular remodeling in 
advanced model of atherosclerosis (Moeller, et al., 1999). Hence, it was also 
reasonable to hypothesize that the recruitment of AT4 receptor occurred at the site of 
SM-induced pulmonary injury, leading to the inhibitory effects of ANG-IV on 
pulmonary inflammation and ROS production. The upregulation of ANG-IV specific 
AT4 receptor suggest that ANG-IV play an important role in the remodeling and 
adaptive response of the damaged tissue following SM exposure.   
Our data also supported observations noted in other reports where at nanomolar 
concentrations, ANG-IV was found to activate AT1 receptor signaling and this 





2009 and Brimfield, et al., 2009). Studies have also noted that ANG-IV-induced 
reductions in renal artery blood flow was blocked by Losartan, suggesting mediation 
by AT1 receptors (Gariner, et al., 1993, Fitzgerald, et al., 1999 and Handa, 2006).    
ANG-IV was also found to mediate the upregulation of inflammation via the AT1 
receptor. A possible mechanism by which this occur may be that which was observed 
in the administration of DAA-1 to hearts of rats with infract scaring (Wen, et al., 
2004). Administration of DAA-1 treatment was able to reduce the infract size in a 
biphasic manner and this was mediated by the AT1 receptor that was coupled to the 
anti-inflammatory prostaglandin pathway as opposed to the pro-inflammatory inositol 
phosphate pathway. As ANG-IV was a metabolite peptide of DAA-1, it may regulate 
and reduced inflammatory conditions in the tissues via the same mechanisms as 
DAA-1, where anti-inflammatory prostaglandins can be recruited to mediate 
inflammation levels in damaged sites.  
This study has demonstrated that ANG-IV treatment was able to increase survival rate 
and reduce severe pulmonary inflammation of mice exposed to LD80 SM. Our study 
has also revealed the complexity of ANG-IV action in mediating against pulmonary 
inflammation as it appeared to involve both AT4 and AT1 receptor binding sites. The 
link between the activation of AT1 and AT4 receptors has not been fully elucidated 
and more research would be needed in this area to further understood the precise 






5.6 Future directions  
The next step of this research would involve translating the current intranasal mouse 
model to an inhalation vapour exposure model. The intranasal intoxication model was 
selected in this preliminary study as it was a relatively fast and simple model in 
administering SM directly into the lungs. While this model was effective in the rapid 
screening and dose ranging studies of different treatment compounds, it may not 
entirely represent actual SM exposure scenarios where pulmonary exposure would be 
primarily due to inhalation of SM gas (Balali-Mood, et al., 2006 and Ghanei, et al., 
2007), as opposed to direct intranasal administration.   
Hence, modifications would be made to the current intoxication protocol such that 
future work using ANG-IV and DAA-1 or other potential treatment compounds 
would involve a SM inhalation vapour exposure model, where SM gas would be 
generated and directed towards the nose of the mice (Anderson, et al., 2000.). SM 
would thus enter the pulmonary system via the natural respiration of the mice and this 
SM lung exposure model would mirror the real-life exposure scenarios more 
accurately.  
In current experimental procedures, the treatment compounds were administered 1 
hour before SM administration (pretreatment), followed by daily treatment dose for 
14 days. This enabled us to establish that angiotensin II was involved in SM induced 
toxicity and shed light on parts of the mechanisms involved in its pathogenesis. 





to administer pretreatment to the victims. Hence, it would be necessary to develop 
therapeutic protocols without pretreatment required to test potential treatment 
compounds. This would involve optimizing the dose and time relationships to 
administer the relevant treatments such that SM induced toxicity and tissue injury 
would be reduced, if not prevented.   
As nutritional supplements were also recommended in the general symptomatic care 
of SM-exposed victims (Borak, et al., 1992), future experiments may involved 
administering glucose supplement concurrently to the mice as part of the treatment 
procedures, considering that substantial weight loss in mice occurred in the first 10 
days post-SM exposure.    
5.7 Conclusion  
This study showed that pretreatment and daily administration of ANG-IV and DAA-
1, angiotensin peptides involved in the RAS pathway, were able to alleviate SM-
induced lung injuries and increase survival rate by reducing body weight loss and 
suppressing SM-induced inflammation in LD80 SM-intoxicated mice. This study has 
demonstrated that ANG-IV exerted its anti-inflammatory protective action via both 
the AT4 and AT1 receptors. Although mechanism by which angiotensin II inhibition 





study, taken together with the results of other studies, suggest that modulating the 
angiotensin II pathway have a therapeutic effect in the treatment of SM injuries.   
Recent studies established that after SM exposure, a significant increase of reactive 
oxygen species (ROS) was observed, suggesting ROS may be possible mediators of 
SM-induced toxicity (Brimfield, et al., 2009 and Steinritz, et al., 2009). It was 
reported that with the inhibition of ROS formation, there was a significant decrease of 
SM-induced apoptosis (Steinritz, et al., 2009). Free radical scavengers (Anderson, et 
al., 2000 and Powers, et al., 2000) were shown to suppress the upregulation of 
inflammatory mediators.   
In addition, the therapeutic administration of compounds with antioxidants and free 
radical scavenging properties was also able to protect the body weight loss of mice 
following SM inhalation exposure (Kumar, et al., 2001), suggesting that ROS 
inhibition may also play a role in attenuating SM-induced inflammatory damages. 
This was similar to data collected earlier, where treatment with ANG-IV and DAA-1 
reduced the weight loss of SM-intoxicated mice, hence, suggesting a possible 
relationship between the expression of both angiotensin II and ROS in the 
development of SM pathogenesis.   
Angiotensin II has been found to activate the nicotinamide adenine dinucleotide-
NADH phosphate oxidase system, resulting in ROS production (Rajagopalan, et al., 





protein synthesis (Baker, et al., 1990). Perhaps co-treatment of both angiotensin II 
peptides modulators and effective antioxidants may be explored as a possible 
therapeutic intervention for SM, since each treatment procedures were found to be 
individually effective in mitigating SM-induced damages.  
Inflammation is a complex and dynamic process that involves different cell 
populations and chemical mediators responding to different kinds of stimuli. 
Differences in chemical insults can affect the type, the kinetics, and the location of 
inflammatory infiltrates activated in tissues (Cowan, et al., 1993). Thus, it may be 
possible for SM to activate a specific and unique set of inflammatory responses 
involving both the angiotensin II pathway as well as ROS formation.   
The relationship between angiotensin and ROS have not yet been resolved and thus, 
further studies would be required to determine whether angiotensin II play a role in 
regulating ROS in SM-induced toxicity. With a greater understanding of the different 
mechanisms involved in SM-induced inflammation and damages, we would be even 
closer to developing effective therapeutic compounds that would protect against and 
perhaps even reverse, the progressive damage caused by SM.  
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